


Pharmaceuticals & Biotechnology | Small Cap
NGL Fine Chem Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Growth metrics are generally positive, driven by revenue, EPS, asset, and net income growth. However, operating profit growth lags. The company's coverage ratios are robust, reflecting a good ability to meet its obligations. Liquidity is adequate, although cash and operating cash flow ratios are weak. Efficiency ratios present challenges, particularly in fixed asset and capital turnover. Financial metrics are average, with book value as a relative strength but dividends and capital expenditures need attention. Despite some weaknesses, NGL Fine Chem's strategic positioning in the Healthcare Services sector supports a positive outlook, contingent on addressing operational inefficiencies and sustaining growth momentum.
NGL Fine Chem Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Growth metrics are generally positive, driven by revenue, EPS, asset, and net income growth. However, operating profit growth lags. The company's coverage ratios are robust, reflecting a good ability to meet its obligations. Liquidity is adequate, although cash and operating cash flow ratios are weak. Efficiency ratios present challenges, particularly in fixed asset and capital turnover. Financial metrics are average, with book value as a relative strength but dividends and capital expenditures need attention. Despite some weaknesses, NGL Fine Chem's strategic positioning in the Healthcare Services sector supports a positive outlook, contingent on addressing operational inefficiencies and sustaining growth momentum.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
50.88
Industry Median
30.92
Small Cap Median
28.82
P/E RATIO
44.01
P/B RATIO
6.43
Industry Median
3.39
Small Cap Median
2.92
P/S RATIO
3.90
Industry Median
3.36
Small Cap Median
2.72
Others
PEG RATIO
-13.02
EV/EBITDA RATIO
23.05
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹3428.5 as on Aug 6, 2026.
The company demonstrates strong growth in revenue, EPS, assets, and net income, indicating a positive trajectory. However, the decline in operating profit growth is a concern. The company's ability to sustain overall growth depends on improving operational efficiency and profitability.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 23.26 | -12.58 | 21.94 | 8.55 | 36.14 |
| Operating Profit Growth Rate | -15 | -48.53 | 54.29 | -35.19 | 108.57 |
| Earnings Per Share (EPS) Growth | -12.02 | -58.92 | 101.57 | -48.88 | 127.87 |
| Asset Growth Rate | 33.82 | 3.61 | 24.04 | 21.63 | 26.1 |
| Net Income Growth Rate | -12.28 | -60 | 105 | -48.78 | 128.57 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Accent Microcell Ltd | 7.96 | 24.25 | Neutral | 57.00 | 18.28 | 44.00 |
| 2 | Lincoln Pharmaceuticals Ltd | 7.31 | 13.81 | Neutral | 98.00 | 43.88 | 88.00 |
| 3 | Kilitch Drugs (India) Ltd | 7.12 | 22.83 | Neutral | 37.00 | 9.27 | 30.00 |
| 4 | NGL Fine Chem Ltd | 6.98 | 44.01 | Overvalued | 73.00 | 67.39 | 48.00 |
| 5 | Sakar Healthcare Ltd | 6.89 | 67.13 | Highly Overvalued | 69.00 | 13.70 | 30.00 |
| 6 | Medico Remedies Ltd | 6.61 | 37.70 | Overvalued | 17.00 | 1.58 | 13.00 |
| 7 | Kopran Ltd | 6.60 | 25.82 | Neutral | 62.00 | 6.30 | 26.00 |
| 8 | SMS Lifesciences India Ltd | 6.59 | 21.63 | Undervalued | 45.00 | 58.80 | 19.00 |
| 9 | Infinium Pharmachem Ltd | 6.42 | 26.92 | Neutral | 22.00 | 6.43 | 14.00 |
| 10 | Medicamen Biotech Ltd | 5.73 | 33.43 | Neutral | 20.00 | 6.94 | 10.00 |
| 11 | Albert David Ltd | 5.63 | -279.90 | Neutral | 5.00 | -2.62 | -1.00 |
| 12 | Zim Laboratories Ltd | 5.41 | 41.96 | Neutral | 30.00 | 1.11 | 6.00 |
| 13 | Remus Pharmaceuticals Ltd | 5.31 | 25.82 | Neutral | 57.00 | 20.97 | 46.00 |
| 14 | Ind-Swift Laboratories Ltd | 4.95 | 47.48 | Neutral | 45.00 | 4.89 | 41.00 |
| 15 | Venus Remedies Ltd | 4.83 | 23.37 | Neutral | 147.00 | 74.30 | 103.00 |
| 16 | Wanbury Ltd | 4.65 | 29.43 | Neutral | 88.00 | 18.93 | 43.00 |
| 17 | Nectar Lifescience Ltd | 3.83 | -2.67 | Neutral | -59.00 | -2.95 | -293.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Quarterly Report⬤3rd Feb 26
Quarterly Financial Results Q3 FY 2025-26
BULLISH SENTIMENT
Concall Report⬤18th Nov 25
Q2 and H1 FY26 Earnings Conference Call
NEUTRAL SENTIMENT